Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Fennec Pharmaceuticals (FENC) Cost of Revenue (2023 - 2025)

Historic Cost of Revenue for Fennec Pharmaceuticals (FENC) over the last 3 years, with Q3 2025 value amounting to $5.2 million.

  • Fennec Pharmaceuticals' Cost of Revenue rose 1323.63% to $5.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $16.5 million, marking a year-over-year decrease of 1032.7%. This contributed to the annual value of $18.4 million for FY2024, which is 5199.21% up from last year.
  • Fennec Pharmaceuticals' Cost of Revenue amounted to $5.2 million in Q3 2025, which was up 1323.63% from $4.4 million recorded in Q2 2025.
  • In the past 5 years, Fennec Pharmaceuticals' Cost of Revenue registered a high of $5.2 million during Q3 2025, and its lowest value of $2.3 million during Q2 2023.
  • In the last 3 years, Fennec Pharmaceuticals' Cost of Revenue had a median value of $3.9 million in 2024 and averaged $3.9 million.
  • In the last 5 years, Fennec Pharmaceuticals' Cost of Revenue surged by 10580.8% in 2024 and then tumbled by 4342.48% in 2025.
  • Quarter analysis of 3 years shows Fennec Pharmaceuticals' Cost of Revenue stood at $3.9 million in 2023, then grew by 1.96% to $3.9 million in 2024, then surged by 32.1% to $5.2 million in 2025.
  • Its Cost of Revenue stands at $5.2 million for Q3 2025, versus $4.4 million for Q2 2025 and $2.9 million for Q1 2025.